CD274 and head and neck squamous cell carcinoma: In a retrospective analysis of 126 HNSCC patients treated with anti-PD-1/PD-L1 agents, TMB was found to be significantly higher among responders (21.3 vs. 8.2 mut/MB, p < 0.01) [28].